
Charlotte Coe, a State Department IT specialist, describes a urethral lesion from a 2025 vaginoplasty that "feels like a constant papercut." It reopens. It bleeds. Sitting is painful. Sexual activity, Coe's own declaration states, is "painful and dangerous." After eight years of hormone replacement therapy and six years of surgical procedures, the tissue Coe says was supposed to resolve gender dysphoria "still resembles and feels like scrotal anatomy." The revision surgery to address it would cost tens of thousands of dollars.
Coe isn't a conservative critic of transgender medicine. Coe is a federal employee who trusted the coverage the government provided — and is now a class representative in a lawsuit against the administration that took it away.
A class action filed in Federal District Court in Washington, D.C. — case number DCD-295146 — names Coe alongside Vanessa Voe, a War Department researcher, and a third plaintiff identified as Christine F. The amended complaint was filed November 2, with a motion for preliminary injunction following on November 4. Their argument is that the Trump administration's phaseout of federal insurance coverage for "gender-affirming care" beginning in 2026, with full elimination in 2027, violates Title VII of the Civil Rights Act. The complaint compares cutting off their treatments to "denying continuing insulin treatment for someone with diabetes."
The comparison is doing a lot of heavy lifting. Insulin keeps diabetics alive. What these procedures produced, according to the plaintiffs' own sworn declarations, is a catalog of suffering that reads like a medical malpractice brief.
Voe's declaration describes what happens during lapses in hormone therapy: "unwanted hair, greasier skin," increased acne, brain fog, "invasive thoughts, extreme irritability," withdrawal from relationships, and bone density loss. Without continuous HRT, Voe states, "my body suffers irreversible harm." That's the plaintiffs' own language — not from opponents of the procedures, but from the people who underwent them. The body requires a permanent pharmaceutical maintenance program or it falls apart. That's the "care" the federal insurance was covering.
Christine F.'s situation puts a price tag on where this road leads. A $100,000 colovaginoplasty — a procedure that constructs a cavity from colon tissue — is what Christine F. says is now needed and no longer covered. Meanwhile, a New York jury awarded another plaintiff, Fox Varian, $2 million in a related case. The money flows in every direction except toward the question nobody in the medical establishment wanted asked: whether these procedures should have been performed in the first place.
The lawsuit leans on the 2020 Supreme Court ruling in Bostock, which extended Title VII employment protections to cover gender identity discrimination. But the legal ground has shifted considerably since then. The Supreme Court has since upheld Tennessee's ban on gender-affirming care for minors. The 10th U.S. Circuit Court of Appeals ruled in February 2025 in Roybal v. Griffith that a male inmate in El Paso County, Colorado had no constitutional right to cross-sex treatments. West Virginia's restrictions on both procedures and girls' sports survived court challenge. The judiciary that once looked like a reliable ally for the expansion of these treatments has started reading the evidence.
And that evidence keeps getting worse. The World Professional Association for Transgender Health — the group whose "standards of care" were cited to justify everything from puberty blockers to genital surgery — is now facing Federal Trade Commission litigation. A three-day conference held in Washington, D.C. last week, organized by the Society for Evidence-Based Gender Medicine, laid out the clinical record. The Biden administration, we now know, intervened in WPATH's own standards development process, pressuring the organization to remove age minimums for procedures. The government wasn't just covering these treatments. It was shaping the medical guidance to ensure fewer guardrails existed.
Maddie Durbin, a detransitioner featured by Independent Women, underwent a double mastectomy and testosterone treatments that left permanent scar tissue, a lowered voice, and chronic leg pain. Durbin's story isn't in the lawsuit. It doesn't need to be. The plaintiffs' own declarations already describe the same pattern — procedures that created new medical problems requiring more procedures, funded by insurance plans that never required anyone to prove the original intervention worked.
The complaint asks the court to treat the coverage removal as employment discrimination. The plaintiffs say they relied on federal benefits, made irreversible medical decisions based on that coverage, and now face ongoing complications without the insurance to address them. As reported by Just The News, Greg Piper noted the declarations read less like a civil rights case and more like a record of what happens when an entire medical infrastructure decides the answer before examining the question.
Eight years of hormones. Six years of surgeries. A lesion that won't heal. Tissue that doesn't match what was promised. A body that requires permanent pharmaceutical intervention to maintain an approximation of the outcome that was sold as liberation.
The government's own employees brought the receipts.


Comments are closed.